AI
ByCan Johnson & Johnson Hit $100 Billion in Revenue Despite U.S. Pricing Pressures?
23 January 2026 Executive Summary Johnson & Johnson (J&J) has issued a bullish 2026 revenue forecast, projecting nearly…
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate
23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has granted…
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central
23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…
Can AbbVie’s 2025 Earnings Prove Its Post-Humira Portfolio Is Built for the Next Decade?
Late January 2026 | Full-Year 2025 Earnings Preview | Biopharma Growth Strategy AbbVie is set to report its…
Will Johnson & Johnson’s 2025 Earnings Reinforce Confidence in Its Pharma-Led Growth Engine?
Late January 2026 | Full-Year 2025 Earnings Preview | Diversified Pharma Outlook Johnson & Johnson (J&J) is set…
